Financial regulation in the age of AI

Artificial intelligence has been playing an increasingly important role in the function of financial markets since the 1980s and the inception of program trading. The technology has evolved and has reached a more adolescent phase of development. As the technology has evolved, the risks introduced by massive algorithms keeping the markets humming have become more evident. The relationship between market volatility and trading volume adds risk as the speed and size of the trading activity has increased. High-frequency trading algorithms, while developed and refined by highly sophisticated institutions, still are at risk of succumbing to human error. Overall, algorithmic trading has benefitted the financial markets in several ways, specifically efficiency. However, the role of market regulators is to protect investors from undue harm. Therefore, there are steps that the government and regulatory agencies could take to help guard the markets from risks posed by algorithmic trading. While regulators can help lower risk, the technology quickly evolves, and not all risks can be contained. It is not the role of regulators to eliminate risk but it is their role to mitigate it in any feasible way

Probing a spin transfer controlled magnetic nanowire with a single nitrogen-vacancy spin in bulk diamond

The point-like nature and exquisite magnetic field sensitivity of the nitrogen vacancy (NV) center in diamond can provide information about the inner workings of magnetic nanocircuits in complement with traditional transport techniques. Here we use a single NV in bulk diamond to probe the stray field of a ferromagnetic nanowire controlled by spin transfer (ST) torques. We first report an unambiguous measurement of ST tuned, parametrically driven, large-amplitude magnetic oscillations. At the same time, we demonstrate that such magnetic oscillations alone can directly drive NV spin transitions, providing a potential new means of control. Finally, we use the NV as a local noise thermometer, observing strong ST damping of the stray field noise, consistent with magnetic cooling from room temperature to $\sim$150 K.Comment: 6 pages, 5 figures, plus supplementary informatio

Upravljanje otporno na kvarove modularnim prekidačko-reluktantnim strojem nadahnuto prirodom

Fault tolerance is an obligatory feature in safety critical applications (aeronautical, aerospace, medical and military applications, power plants, etc.), where loss of life, environmental disasters, equipment destructions or unplanned downtimes must be avoided. For such applications, a novel bio-inspired motion control system is proposed. All its three components (the switched reluctance machine, the power converter and the control system) are designed to be as fault tolerant as possible. This paper describes all these three fault tolerant components: the bio-inspired control system having self-healing capabilities, the power converter with an extra leg and the fault tolerant modular machine. The theoretical expectations and simulation results are validated by means of laboratory experiments.Otpornost na kvarove je nužnost u sigurnosno kritičnim aplikacijama (aeronautičke, zrakoplovne, medicinske i vojne aplikacije, elektrane itd.), gdje je potrebno izbjeći smrtne slučajeve, prirodne nepogode, uništenje opreme ili neplanirane prekide u radu. Za takve aplikacije, predložen je novi slijedni sustav nadahnut prirodom. Sve tri komponente (prekidačko-reluktantni stroj, pretvarač i sustav upravljanja) su projektirani da budu što je više moguće otporni na kvarove. Ovaj rad opisuje sve tri komponente: sustav upravljanja nadahnut prirodom sa samoliječećim svojstvima, pretvarač s dodatnom granom i modularni stroj otporan na kvarove. Teoretska očekivanja i simulacijski rezultati su provjereni laboratorijskim eksperimentima

Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma

Recent advances in neuroimaging and cerebrospinal fluid (CSF) biomarker assays have provided evidence of a long preclinical stage of Alzheimer’s disease (AD). This period is being increasingly targeted for secondary prevention trials of new therapies. In this context, the interest of a noninvasive, cost-effective amyloid-β (Aβ) blood-based test does not need to be overstated. Nevertheless, a thorough validation of these bioanalytical methods should be performed as a prerequisite for confident interpretation of clinical results. The aim of this study was to validate ELISA sandwich colorimetric ABtest40 and ABtest42 for the quantification of Aβ(40) and Aβ(42) in human plasma. The validation parameters assessed included precision, accuracy, sensitivity, specificity, recovery, and dilution linearity. ABtest40 and ABtest42 proved to be specific for their target peptide using Aβ peptides with sequence similar to the target. Mean relative error in the quantification was found to be below 7.5% for both assays, with high intra-assay, inter-assay, and inter-batch precision (CV <9.0% on average). Sensitivity was assessed by determination of the limit of quantification fulfilling precision and accuracy criteria; it was established at 7.60 pg/ml and 3.60 pg/ml for ABtest40 and ABtest42, respectively. Plasma dilution linearity was demonstrated in PBS; however, dilution in a proprietary formulated buffer significantly increased the recovery of both Aβ(40) and Aβ(42) masked by matrix interactions, allowing a more comprehensive assessment of the free and total peptide levels in the plasma. In conclusion, both assays were successfully validated as tools for the quantification Aβ(40) and Aβ(42) in plasma

Severe hypoglycaemia in type 1 diabetes mellitus:underlying drivers and potential strategies for successful prevention

Hypoglycaemia remains an over-riding factor limiting optimal glycaemic control in type 1 diabetes. Severe hypoglycaemia is prevalent in almost half of those with long-duration diabetes and is one of the most feared diabetes-related complications. In this review, we present an overview of the increasing body of literature seeking to elucidate the underlying pathophysiology of severe hypoglycaemia and the limited evidence behind the strategies employed to prevent episodes. Drivers of severe hypoglycaemia including impaired counter-regulation, hypoglycaemia-associated autonomic failure, psychosocial and behavioural factors and neuroimaging correlates are discussed. Treatment strategies encompassing structured education, insulin analogue regimens, continuous subcutaneous insulin infusion pumps, continuous glucose sensing and beta-cell replacement therapies have been employed, yet there is little randomized controlled trial evidence demonstrating effectiveness of new technologies in reducing severe hypoglycaemia. Optimally designed interventional trials evaluating these existing technologies and using modern methods of teaching patients flexible insulin use within structured education programmes with the specific goal of preventing severe hypoglycaemia are required. Individuals at high risk need to be monitored with meticulous collection of data on awareness, as well as frequency and severity of all hypoglycaemic episodes